Impact of multimorbidity count on all-cause mortality and glycaemic outcomes in people with type 2 diabetes: a systematic review protocol. Issue 4 (5th April 2018)

• Record Type: Journal Article
• Authors: Chiang, Jason I; Furler, John; Mair, Frances S; Jani, Bhautesh; Nicholl, Barbara I; Jenkins, Alicia; Condron, Patrick; O'Neal, David; Manski-Nankervis, Jo-Anne
• Is Part Of: BMJ open. Volume 8:Issue 4(2018)
• Publication Date: 2018-04-05
• Subjects: type 2 diabetes -- multimorbidity -- mortality -- glycaemia; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2017-021100
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Type 2 diabetes (T2D) is a leading health priority worldwide. Multimorbidity (MM) is a term describing the co-occurrence of two or more chronic diseases or conditions. The majority of people living with T2D have MM. The relationship between MM and mortality and glycaemia in people with T2D is not clear. Methods and analysis: Medline, Embase, Cumulative Index of Nursing and Allied Health Complete, The Cochrane Library, and SCOPUS will be searched with a prespecified search strategy. The searches will be limited to quantitative empirical studies in English with no restriction on publication date. One reviewer will perform title screening and two review authors will independently screen the abstract and full texts using Covidence software, with disagreements adjudicated by a third reviewer. Data will be extracted using a using a Population, Exposure, Comparator and Outcomes framework. Two reviewers will independently extract data and undertake the risk of bias (quality) assessment. Disagreements will be resolved by consensus. A narrative synthesis of the results will be conducted and meta-analysis considered if appropriate. Quality appraisal will be undertaken using the Newcastle-Ottawa quality assessment scale and the quality of the cumulative evidence of the included studies will be assessed using the Grading of Recommendations, Assessment, Development and Evaluation approach. This protocol was prepared in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines to ensure the quality of our review. Ethics and dissemination: This review will synthesise the existing evidence about the impact of MM on mortality and glycaemic outcomes in people living with T2D and increase our understanding of this subject and will inform future practice and policy. Findings will be disseminated via conference presentations, social media and peer-reviewed publication. PROSPERO registration number: CRD42017079500.